The Chalcogen Is Sulfur Patents (Class 548/307.1)
-
Patent number: 6903126Abstract: The invention relates to novel benzimidazole derivatives with general formula I, whereby radicals R1, R2, R3, A, B, Y and Z have the meanings that are indicated in the description and the claims, the use of these compounds for the production of a pharmaceutical agent for treatment and prevention of diseases associated with microglia activation as well as pharmaceutical preparations that contain these compoundsType: GrantFiled: July 9, 2002Date of Patent: June 7, 2005Assignee: Schering AGInventors: Thorsten Blume, Wolfgang Halfbrodt, Joachim Kuhnke, Ursula Monning, Herbert Schneider
-
Patent number: 6884894Abstract: This disclosure relates to a method for producing and using catalysts in the production of bisphenols, and in particular to a method for producing catalysts which contain poly-sulfur mercaptan promoters, and using these catalysts in the production of bisphenol-A and its derivatives.Type: GrantFiled: July 25, 2003Date of Patent: April 26, 2005Assignee: General Electric CompanyInventors: Jimmy Lynn Webb, James Lawrence Spivack
-
Publication number: 20040249166Abstract: A compound represented by formula (I): 1Type: ApplicationFiled: December 1, 2003Publication date: December 9, 2004Applicant: AGFA-GEVAERTInventors: Etienne Van Thillo, Johan Loccufier, Hartwig Andries
-
Patent number: 6780576Abstract: A compound represented by formula (I): a compound represented by (II): or a mixture of at least one compound represented by formula (I) with at least one compound represented by formula (II), wherein M is hydrogen, an alkali atom or an ammonium group; R1 is hydrogen, a —(CH2)mSO3M group or a R2 is an alkyl-, alkenyl- or alkynyl- group having 6 to 25 carbon atoms; and m is an integer between 1 and 5; the use of at least one compound represented by the above-mentioned formula (I), at least one compound represented by the above-mentioned formula (II) or a mixture of at least one compound represented by the above-mentioned formula (I) and at least one compound represented by the above-mentioned formula (II) as a surfactant; and a photographic material comprising a support and a layer containing photosensitive silver halide, characterized in that the photographic material contains at least one compound represented by the above-mentioned formula (I), at leType: GrantFiled: June 23, 2003Date of Patent: August 24, 2004Assignee: Agfa-GevaertInventors: Etienne Van Thillo, Johan Loccufier, Hartwig Andries
-
Patent number: 6645988Abstract: The present invention relates to pharmaceutical preparations comprising substituted benzimidazole proton pump inhibitors. There is provided a liquid or solid pharmaceutical dosage form that is not enteric coated or delayed released containing a proton pump inhibitor and a Primary Essential Buffer. When the dosage form is placed in a liquid phase the Primary Essential Buffer maintains the pH of the environment at a value greater than the pKa of the proton pump inhibitor for a time sufficient to substantially avoid acid degradation of the proton pump inhibitor in the environment. Also provided is a method for treating acid-related gastrointestinal disorders by administering a solid pharmaceutical dosage form; and a kit for the preparation of a liquid oral pharmaceutical composition.Type: GrantFiled: July 9, 2001Date of Patent: November 11, 2003Assignee: Curators of the University of MissouriInventor: Jeffrey O. Phillips
-
Publication number: 20030171591Abstract: The present invention relates to a production method of an optically active form of a compound represented by formula (II) 1Type: ApplicationFiled: October 24, 2002Publication date: September 11, 2003Inventors: Hideo Hashimoto, Tadashi Urai
-
Patent number: 6489346Abstract: There is provided a solid pharmaceutical composition in a dosage form that is not enteric-coated, having active ingredients including a non-enteric coated proton pump inhibitor and at least one buffering agent. The proton pump inhibitor is omeprazole, lansoprazole, rabeprazole, esomeprazole, pantoprazole, pariprazole, and leminoprazole, or an enantiomer, isomer, derivative, free base, or salt thereof, in an amount of approximately 5 mg to approximately 300 mg; and the buffering agent is in an amount of approximately 0.1 mEq to approximately 2.5 mEq per mg of proton pump inhibitor. The dosage form includes a suspension tablet, a chewable tablet, an effervescent powder, or an effervescent tablet. Also provided is a method for treating an acid-related gastrointestinal disorder in a subject in need thereof by administering to the subject a solid pharmaceutical composition.Type: GrantFiled: January 11, 2000Date of Patent: December 3, 2002Assignee: The Curators of the University of MissouriInventor: Jeffrey Owen Phillips
-
Patent number: 6472414Abstract: Novel compounds are provided which are inhibitors of MTP and thus are useful for lowering serum lipids and treating atherosclerosis and related diseases, and have the structure including pharmaceutically acceptable salts thereof or prodrug esters thereof, wherein q is 0, 1 or 2; Rx is H, alkyl, aryl or halogen; A is (1) a bond; (2) —O—; or (3) B is: and wherein L2, L1, R1, R2, R3, R3′, R3a, R3b, R4, R4′, R5, X, are as defined herein.Type: GrantFiled: May 18, 1999Date of Patent: October 29, 2002Assignee: Bristol-Myers Squibb CompanyInventors: Scott A. Biller, John K. Dickson, R. Michael Lawrence, David R. Magnin, Michael A. Poss, Jeffrey A. Robl, William A. Slusarchyk, Richard B. Sulsky, Joseph A. Tino
-
Publication number: 20020128232Abstract: The present invention relates to novel angiogenic-inhibitory compounds of formula (I) 1Type: ApplicationFiled: October 12, 2001Publication date: September 12, 2002Inventors: Scott A. Henderson, Barry R. Matthews
-
Patent number: 6376666Abstract: 2-mercaptobenzimidazole derivatives of the general formula wherein: N=0,2,3; R-hydrogen atom, aralkyls; R1-lower alkyls, alkenyls, dialkylamino, a saturated amine monocyclic residue which may contain an additional heteroatom; R2 and R3 are equal or different and stand for hydrogen atoms, lower alkyls, alkoxy in various positions, and their pharmaceutically acceptable salts, according to the results of pharmacological research study exhibit a pronounced anxiolytic, sedative, antiischemia and antiarrhythmia effect and have certain advantages over popular clinic preparations. These can find a wide variety of application for treatment of patients suffering from various mental derangements and heart ischemia.Type: GrantFiled: December 9, 1996Date of Patent: April 23, 2002Assignee: Nauchno-Issledovatelsky Institut Farmakologii Rossiiskoi Akademii Meditsinskikh NaukInventors: Sergei Borisovich Seredenin, Jury Alexeevich Blednov, Vladimir Leonidovich Saveliev, Tatyana Yakovlevna Mozhaeva, Eleonora Konstantinovna Orlova, Khagani Sabir Ogly Ragimov, Milada Alnordovna Yarkova, Gennady Georgievich Chichkanov, Natalia Veniaminova Kaverina, Iosif Borisovich Tsorin, Galina Jurievna Kirsanova, Grigory Georgievich Neznamov
-
Patent number: 6362208Abstract: The invention relates to a novel anilide compound and a pharmaceutical composition comprising the same. The invention relates to a compound represented by the following general formula: represents a divalent residue of benzene with a substituent(s), heterocycle-condensed benzene which may or may not have a substituent, pyridine which may or may not have a substituent, cyclohexane or naphthalene or Ar represents an aryl group which may or may not have a substituent; X represents —NH—, oxygen atom or sulfur atom; Y represents —NR4—, oxygen atom, sulfur atom, sulfoxide or sulfone; Z represents single bond or —NR5—; R4 represents hydrogen atom, a lower alkyl group, an aryl group or a silylated lower alkyl group which may or may not have a substituent; R5 represents hydrogen atom, a lower alkyl group, an aryl group or a silylated lower alkyl group which may or may not have a substituent; and n represents an integer of 0 to 15.Type: GrantFiled: December 6, 1999Date of Patent: March 26, 2002Assignee: Kowa Company, Ltd.Inventors: Kimiyuki Shibuya, Katsumi Kawamine, Yukihiro Sato, Toshiyuki Edano, Mitsuteru Hirata, Chiyoka Ozaki
-
Patent number: 6242611Abstract: A subject of the invention is the products of formula (I): in which: R1 and R2 represent in particular cyano and trifluoromethyl, R3 represents in particular alkyl, alkenyl or alkynyl, substituted in particular by nitrooxy or carbonyloxy, R4 and R5 represent in particular methyl optionally substituted by fluorine, X and Y represent in particular oxygen, as well as their salts and isomers.Type: GrantFiled: September 28, 1998Date of Patent: June 5, 2001Assignee: Hoechst Marion RousselInventors: Andre Claussner, Francois Goubet, Jean-Georges Teutsch
-
Patent number: 6194396Abstract: This invention relates to a heterocyclic compound of the formula wherein a group of the formula: is a group of the formula X is O, S or N-R5, R1 is lower alkyl, etc., R5 is hydrogen, lower alkyl, etc., R2 is hydrogen, halogen, lower alkyl, etc., R3 is halogen, lower alkyl, etc., R4 is amino optionally having suitable substituent(s), and A is lower alkylene, and a salt thereof, to processes for preparation thereof, and to a pharmaceutical composition comprising the same for the prevention and/or the treatment of bradykinin or its analogues mediated diseases in human being or animals.Type: GrantFiled: October 22, 1999Date of Patent: February 27, 2001Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Teruo Oku, Hiroshi Kayakiri, Shigeki Satoh, Yoshito Abe, Yuki Sawada, Takayuki Inoue, Hirokazu Tanaka
-
Patent number: 6191157Abstract: The hetero-linked phenylglycinolamides are prepared by reaction of the corresponding hetero-linked phenylacetic acids with appropriate phenylglycinols. The hetero-linked phenylglycinolamides are suitable as active compounds in medicaments.Type: GrantFiled: December 4, 1998Date of Patent: February 20, 2001Assignee: Bayer AktiengesellschaftInventors: Siegfried Goldmann, Ulrich Müller, Richard Connell, Hilmar Bischoff, Dirk Denzer, Rudi Grützmann, Martin Beuck
-
Patent number: 6172057Abstract: Matrix metalloproteinases (MMPs) are a group of enzymes that have been implicated in the pathological destruction of connective tissue and basement membranes. These zinc containing endopeptidases consist of several subsets of enzymes including collagenases, stromelysins and gelatinases. TNF-&agr; converting enzyme (TACE), a pro-inflammatory cytokine, catalyzes the formation of TNF-&agr; from membrane bound TNF-&agr; precursor protein. It is expected that small molecule inhibitors of MMPs and TACE therefore have the potential for treating a variety of disease states. The present invention provides low molecular weight, non-peptide inhibitors of matrix metalloproteinases (MMPs) and TNF-&agr; converting enzyme (TACE) for the treatment of arthritis, tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection.Type: GrantFiled: February 19, 1998Date of Patent: January 9, 2001Assignee: American Cyanamid CompanyInventors: Aranapakam Mudumbai Venkatesan, George Theodore Grosu, Jamie Marie Davis, Baihua Hu, Derek Cecil Cole, Jannie Lea Baker, Marcy Pamela Jacobson, Matthew Robin O'Dell